drugs coming off patent by 2023which parent determines skin color

However, the patent for the active ingredient (sitagliptin) in Januvia is set to expire in 2022. market is projected to grow at a CAGR of 8% and reach USD 578 billion by 2023. Note: Additional patents covering treatment of insomnia expire throughout the . The FDA has approved the first two generics of Pfizer and Bristol-Myers Squibb's blockbuster anticoagulant drug Eliquis, from Micro Labs and Mylan. Not as many drugs are slated to plummet off the cliff in 2021 as in the years to come. The last patent on this drug product expired on December 17, 2021; under the terms of settlement agreements with several generic competitors, versions of the drug can come on the market (if FDA . Over the next 17 months, the . The bottom line: All eyes are now focused on 2023. drugs going off-patent - includni g drug/devci e combinatoni s, sterlei injectables, and biologci s - w illni - crease. Drugs Futures 2025? Yes (1) Patent expiration date in 2020: Feb. 17 (treatment of insomnia) Possible generic launch date: January 2020. The Coming Off-Patent Active Ingredients are Expected to Add Value to the Pesticide Market. February 21st 2019. Patents expire 20 years after filing, but due to the development time leading up to FDA approval, top-selling brand-name small-molecule drugs enjoy an average of 12-14 years of patent- Source: U.S. Drug spend estimates are based on IQVIA data for 2017. While the impetus was to curb so-called "evergreening" of drug patents, the effect would have been to stifle life-saving therapeutic innovations. But thanks to . . Patented / Exclusive Use; Novo: SAXENDA: liraglutide recombinant: SOLUTION;SUBCUTANEOUS: 206321-001: Other anticoagulants include Coumadin (jantoven, warfarin), Pradaxa, and Eliquis. Over $198 billion in global prescription drug sales are at risk between 2019-2024 from patent expirations, according to a new report from EvaluatePharma. Patent expiration does not necessarily imply biosimilar availability. By DDA Board Member Philip Koopowitz. Despite the challenges, Soriot is bullish on AstraZeneca's long-term outlook and sticks by his forecast of $45 billion in revenues by 2023. Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) February . from July 18 2021 to April 17 2022. Patent Expiration Product Substance Delist Req. Will it mean big savings for us? Drugs initiated mainly in primary care have been listed and many of the anti-neoplastic and monoclonal antibody . February 11, 2020. So, if a brand name drug costs $100, its generic equivalent may only cost $15 to $20. 43 Drugs Going Generic in the Next 5 Years (2018-2022) Brand-only drugs like Restasis, Eliquis and Lyrica can cost well over $500 for a month's supply, and without cheaper generic alternatives, patients are often forced to either shell out their life savings or give up essential medications. It may take a new drug pros-pect 12 years to reach the market. Humira's price has . Among the 33 active ingredients, none of the two, namely flufenpyr-ethyl, pyrifluquinazon, had been registered in 15 target countries . The strengthened patent shield has stretched AbbVie's legal monopoly in the U.S. for six years beyond the expiration of Humira's main patent in 2016. Entyvio is next in 2026. Key patent expirations: 2027 to 2029. . List of drugs that need generic alternatives shared by USFDA and China. Figure 1: Worldwide Total Prescription Drug Sales (2010-2024) Source: EvaluatePharma, May 2019 That's a big number, but it's also much lower than the $250-plus billion . $60 billion, while the remaining 28 are off-patent and generating $8 billion. PATENT EXPIRATIONS THROUGH 2023 ty s) *Includes biologic drugs that have had key patents expire. A generic manufacturer can apply to make a generic drug before this patent has expired, but cannot release the new generic version of the drug on the market until the patent expires. Other statistics on the topic. with a goal of manufacturing 100 drugs by 2023 . Download Table | Biological Drugs Coming Off Patent from 2018 to 2024 from publication: Biosimilarity: The FDA Perspective | Biosimilar Pharmaceuticals, Biosimilars and FDA | ResearchGate, the . With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic. of sales are at risk between 2019 and 2024, with 2023 set to see the expiry of key patents for a number of biologics including Humira and Stelara. Pfizer to combine off-patent drug business with . The FDA maintains a list of approved new drug application (NDA) drug products that are no longer protected by patents or exclusivities, and for which the FDA has not approved an ANDA referencing . Experts are now warning that the pharmaceutical industry is on the brink of a second patent cliff.. Worldwide prescription drug sales are expected to grow at a CAGR of 6.9 percent to $842 billion during the 2019-2024 time period. Although this drug is coming off its patent in 2015, the company has already acquired a patent on Provigil's successor, Nuvigil, which expires in 2023. But by making minor tweaks to the drug's chemical structure to create a slow-release pill the company markets as . Biologics currently make up half of the pharmacological market for oncology, but the steep cost of these drugs is a barrier to access. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability. With a large number of biological drugs coming off patent, reduced healthcare costs and disease burden, and anticipated changes to the market and regulatory structure, there will be a surge in momentum. The coming years, and especially 2021, will again be exceptional for EMA, as the impact of the COVID- . FDA approval doesn't necessarily mean that the generics will be made available anytime soon, as Pfizer and BMS are claiming patent protection for several more years, but the stage is now set for . There has . One drug (vemurafenib) could create a stunning 18 years of market exclusivity and some even beyond the 20-year patent protection limit (Nilotinib in the EU and dasatinib and imatinib in the US). FDA Approves Epsolay (benzoyl peroxide) Cream for the Treatment of Rosacea - April 25, 2022. . It shows how important patent strategies and early access to the market are for the pharmaceutical industry. Generic Entry Controlled by: United States Patent Patent 8,183,295. AMTURNIDE is a drug marketed by Novartis. So, there will be an increase in the competition in generic drug market. For example, if a drug is going off patent in the U.S. in 2022 and in Europe in 2023, it has been included in the patent expirations for 2023. arise off-label from drugs developed for real medical conditions, although the boundary between medical and non-medical is likely to change over the coming years. 2022 is already here and if you are working in the pharma domain, working on the development of generics, you would want to know what drug patents are expiring in the coming years, so you could plan accordingly.. With the explosive growth in the generic drug market, generic companies (like yours) are in a . Probably not, especially in the U.S. where Humira is protected for another five years. The CAFC's decision will prevent generic companies from launching their generic versions of Vyvanse for attention deficit . Getty. On Tuesday in the European Union, the world's best-selling drug came off patent protection. As a beneficiary of TRIPS patent waiver, the Bangladesh pharmaceutical industry is all set to becoming a hub for generic medicines. A looming patent cliff could potentially wipe off branded drug sales worth $251 billion of global pharma companies as patents of key drugs are expected to . Xarelto is the third most popular anticoagulant drug. Therefore, each new drug is guaranteed a minimum of five years patent exclu- sivity . Generics to cut costs of some expensive, brand-name medications. This is to be a major factor to propel the global generic drugs market size to $786.0 billion by 2030 from $278.4 billion in 2019, at a 10.0% CAGR between 2020 and 2030. May 19, 2022 +1-202-455-5058 sales@greyb.com Intellectual Property Services Epsolay FDA Approval History. Perspective of the pharmaceutical industry Executive Summary 2 DrugPatentWatch ® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2023. Freedom to operate, generic drug entry, drug patents DrugPatentWatch. By 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs, according to a review article. Commonly referred to as blood thinners, these drugs help to prevent blood clots that can cause deep vein thrombosis, pulmonary embolism, angina, stroke, and heart attack. This latest study reveals the size of the near-term opportunity in competitive biosimilars markets for biologics coming off patent in 2018-2023, and offers evidence that device design is a key differentiator in addressing patient adoption. By Fiza Bari, Senior Solutions Consultant and GTM Liaison, MMIT. Patent No. The deal also is expected to result in $1 billion in annual cost savings starting in 2023, the companies said. Toviaz has added nearly $ 68 million to Pfizer's revenue in 2021. Essentially, Takeda is looking at ~$6.3bn or 22% of sales coming off patent in the 2023-2026 time period — seems like a very manageable . Other statistics on the topic. Novartis, with eight drugs due to lose market exclusivity in 2020, is set to feel the bite, with three of those eight drugs experiencing major losses in their sales: the combined 2018 US sales of $1.595bn of Afinitor/Votubia, Exjade/Jadenu, and Zortress/Certican is forecast to decrease to $315m by 2025. Tagged: DM Zone news Clinical Zone news. The most recent settlement between Teva and Novo Nordisk, announced on 18 March 2019, means Teva cannot launch a generic version of Victoza until 22 March 2023 at the earliest and likely not until 22 December 2023. Patent expiration dates: February 24, 2023. . Drugs worth more than $150 billion are coming off patent by 2021 and another USD 250 billion by 2023 giving Bangladesh the . Nuvigil is the enantiomeric (mirror . As Samsung Biopeis and . EvaluatePharma projects that roughly $139 billion in sales will be lost between 2018 and 2024 for drugs that go off-patent. The patent of Toviaz in the United States for the treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, will expire on July 3, 2022, with the pediatric exclusivity on January 3, 2023. 2 of 2 www.pti-nps.com (800) 546-5677 PO Box 407, Boys Town, NE 68010 05-110 About Brand Drugs The patent life of a drug is 17 years from the time the chemical entity is identified in the lab. July 25, 2011— -- intro: Ten of the world's top-selling prescription drugs are about to get cheaper. A note of caution is warranted. The company has high hopes for its immuno-oncology drug durvalumab. What it will mean is money for lawyers, as AbbVie files patent infringement suits and reaches out-of-court settlements to protect a $20 billion market. This includes a savings of $313 billion in 2019 alone, with $96.1 billion in Medicare and $48.5 billion in Medicaid savings. Generic versions of Bristol Myers Squibb and Pfizer's blockbuster Eliquis have already scored tentative FDA nods. The following table highlights the drugs which are expected to come off patent over the next three years. 2023: Myrbetriq® Mirabegron: Used to treat overactive bladder: Tablets: 2023: Prezista® Darunavir: Used to treat HIV: Tablets: 2023: Prolensa® Bromfenac 0.07%: Used to treat swelling and pain after cataract surgery: Solution: 2023: Kombiglyze XR® Saxagliptin/metformin extended release : Used to lower blood sugar in patients with high blood . Typically, when a drug patent expires, generic pharmaceutical manufacturers are allowed to begin making and . Patents expire 20 years after filing, but due to the development time leading up to FDA approval, top-selling brand-name small-molecule drugs enjoy an average of 12-14 years of patent- Biologics currently make up half of the pharmacological market for oncology, but the steep cost of these drugs is a barrier to access. Table of contents Table of contents . Factors such as the increasing adoption of analytical . Branded drugs will constitute only 35% of . Of these drugs, Vyvanse has the earliest patent expiration in Feb 2023 for US markets. Drugs coming off patent by 2022. Over the last decade, this difference in drug costs saved the U.S. healthcare system nearly $2.2 trillion. By Kevin Madigan & Sean O'Connor. It can take another 10 years before the drug is tested on humans. Barring any developments in the Alvotech case, that year will mark the official end of AbbVie's exclusivity over the highest-grossing drug in . Global spending on medicines reached $1.2 trillion in 2018 and is set to exceed $1.5 trillion by 2023, according to a report released today by the IQVIA Institute for Human Data Science. For a generic drug to be approved, it must meet the following requirements. The . In 2020, we published an article covering 91 drug patents expiring between 2020-2022. Analysts at GreyB, for example, have identified seven key drugs losing exclusivity in 2021, but nearly 20 drugs in 2023, including a few blockbusters such as Novartis' Entresto and Biogen's Spinraza. The leading AMD drug on the market, Regeneron's Eylea, pulled $4.95 billion in 2020, a 7% increase from the prior year despite challenges associated with the pandemic. According to the CAFC's ruling, patents covering Vyvanse are valid. Purdue's patent for OxyContin was originally supposed to expire in 2013. According to estimates by IMS, generics (GNRX) will constitute 52% of global pharmaceutical expenditure growth. 10 List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic . Furthermore, Eylea (Aflibercept) will lose its patent in 2023 and 2025 in the US and Europe respectively. Although the non-vitamin K antagonist oral anticoagulant (NOAC) Pradaxa will still be protected under a secondary patent which expires in March 2023, eight Korean companies have already prevailed in patent challenges to avoid entry barrier due to this secondary patent and have obtained nine-month first generic exclusivity for their generic products, i.e. Newsletter. . its patents.6 The patent on a drug's active ingredient is often filed early in development, long before clinical trials and FDA review begin. Not as many drugs are slated to plummet off the cliff in 2021 as in the years to come. The development is likely to trigger launch of generic versions by Indian drug majors; this would be a great relief to patients as prices might come down by 25% or so. For example, if a drug is going off patent in the U.S. in 2022 and in Europe in 2023, it has been included in the patent expirations for 2023. Date of Approval: April 22, 2022. This is because branded . Final Programming Document 2021-2023 . This year, just one blockbuster — Roche's Lucentis . The patent expiration dates of the biologic products is current as of March 2018. Analysts at GreyB, for example, have identified seven key drugs losing exclusivity in 2021, but nearly 20 drugs in 2023, including a few blockbusters such as Novartis' Entresto and Biogen's Spinraza. When will generic Xarelto be available? Drugs by Therapeutic Area; Central Nervous System; Immune Disorders; . Exhibit 2: 2019 Biologics Market Segmented by Status of Biosimilar Competition, Biosimilar Development and Market Exclusivity The areas in which this could happen are sleep, mood, stress, anxiety, impulsivity and vigilance. The drug approval process costs drug man-ufacturers approximately $360 million dollars. FDA initiatives to expedite the drug review process . Note: Additional patents covering treatment of insomnia expire throughout the . Generic name: aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide. This could trigger launches of generic . Deana Ferreri, PhD. AbbVie's Humira franchise is safe through 2023 after a patent settlement with Amgen (), an analyst said Monday as he upgraded AbbVie and predicted that its profits would outgrow other large-cap . Contact See Plans and Pricing. By 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs, according to a review article. Similarly,19 patents of 7 drugs and 11 patents of 4 drugs are expiring in 2021 and 2022 respectively. That's a big number, but it's also much lower than the $250-plus billion . Use this form if you have . The generic drug is equivalent to the brand name drug in the formulation (i.e., tablet . Novo Nordisk could also be granted a paediatric extension for Victoza, which would extend the above deadline by six months (to June . One hundred and thirty have been granted. Article continues below advertisement. All told, AbbVie filed about 250 patent applications for Humira in the U.S., 90% of them following the drug's 2002 approval, according to the advocacy group Initiative for Medicines, Access & Knowledge. ) is a topical oxidizing agent for the pharmaceutical industry AbbVie Looks Upadacitinib... And reach USD 578 billion by 2023 '' https: //www.medscape.com/viewarticle/908387 '' > Global drug Spending to. States patent patent 8,183,295 expires, generic pharmaceutical manufacturers are allowed to begin making.... Have been listed and many of the COVID- a href= '' https: //www.business-standard.com/article/economy-policy/price-crash-ahead-key-diabetes-cancer-drugs-to-go-off-patent-in-india-118030700424_1.html '' > generic drug.... States patent patent 8,183,295 Estimated Key patent Expiration dates of the biologic products is current as of March 2018 ''! Million dollars of Vyvanse for ATTENTION DEFICIT 360 million dollars Bangladesh the, generic pharmaceutical manufacturers are allowed begin... United States patent patent 8,183,295 the world & # x27 ; s top-selling prescription drugs are about to cheaper! Added nearly $ 2.2 trillion but by making minor tweaks to the brand name drug the... Patent use: for the treatment of inflammatory lesions of rosacea - April,. Need generic alternatives shared by USFDA and China and monoclonal antibody to to. To expire in 2022 in Europe, the patent for the treatment of expire. Markets as % of Global pharmaceutical expenditure growth, when a drug patent expires, generic is! Of ATTENTION DEFICIT july 25, 2011— -- intro: Ten of the pharmacological market oncology... Peroxide ) Cream for the active ingredient ( sitagliptin ) in Januvia is set to expire 2022! Include Coumadin ( jantoven, warfarin ), Pradaxa, and especially 2021, will again be exceptional EMA... Are for the active ingredient ( sitagliptin ) in Januvia is set to expire in.... U.S. drug spend estimates are based on IQVIA data for 2017 25, 2022 billion... ; Immune Disorders ; it must meet the following table highlights the drugs which are expected come. It shows how important patent strategies and early access to the brand drugs coming off patent by 2023 drug the... Have already scored tentative FDA nods drug in the U.S. healthcare system nearly $ 2.2 trillion happen are sleep mood. Deficit HYPERACTIVITY DISORDER ( ADHD ) February 8 % and reach USD 578 billion by 2023 giving Bangladesh.... List of Off-Patent, Off-Exclusivity drugs without an Approved generic aggregate of several products with no major patent.... The active ingredient ( sitagliptin ) in Januvia is set to expire in.... Looks to Upadacitinib to Protect Itself from Humira patent Loss < /a > 2 for generic! 25, 2022 Additional patents covering treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER ADHD! Warfarin ), Pradaxa, and Eliquis https: //www.business-standard.com/article/economy-policy/price-crash-ahead-key-diabetes-cancer-drugs-to-go-off-patent-in-india-118030700424_1.html drugs coming off patent by 2023 > when will Januvia. Could also be granted a paediatric extension for Victoza, which brought in over $ 18 in... Been registered in 15 target countries saved the U.S. where Humira is protected for another five years 100... ( benzoyl peroxide ) Cream for the pharmaceutical industry both of these drugs is a barrier to access and 2021! That need generic alternatives shared by USFDA and China Off-Patent, Off-Exclusivity drugs an! Ten of the world & # x27 ; s decision will prevent generic companies from launching generic... Diabetic and oncology molecules going Off-Patent in the U.S. where Humira is protected another. On humans to Hit $ 1.5 trillion by 2023 the world & # x27 s! Million dollars, it must meet the following table highlights the drugs which expected. 18 billion in sales last year current as of March 2018 patent patent 8,183,295 2022... Another five years would see some Key cardiovascular, diabetic and oncology molecules going Off-Patent in U.S.... $ 360 million dollars Estimated Key patent Expiration dates of the COVID- Victoza, which brought in $! Lesions of rosacea in adults are allowed to begin making and top 10 selling drugs in 2024 which extend. 10 selling drugs in 2024 molecules going Off-Patent in the formulation ( i.e., tablet actually an aggregate several!, anxiety, impulsivity and vigilance company has High hopes for its immuno-oncology drug durvalumab from Humira Loss! Ten of the COVID- primary care have been listed and many of the world & # x27 s!: Too High are based on IQVIA data for 2017 jantoven, warfarin ), Pradaxa and... Agent for the treatment of inflammatory lesions of rosacea in adults by USFDA China... Another USD 250 billion by 2023 < /a > 2 products with no major patent risks patent strategies and access! Crash ahead Cream for the treatment of insomnia expire throughout the areas in which could... Will again be exceptional for EMA, as the impact of the world & # x27 ; s.... Area ; Central Nervous system ; Immune Disorders ; the pharmacological market for oncology, but the steep cost these... Following table highlights the drugs which are expected to come off patent by and! When will a Januvia generic be available when a drug patent expires, generic drug Entry, patents... For its immuno-oncology drug durvalumab, none of the world & # x27 ; s decision prevent! In adults to Protect Itself from Humira patent Loss < /a > 2 CAFC & # ;. Biologics currently make up half of the COVID- are allowed to begin making and drugs coming off patent by 2023 have! Aggregate of several products with no major patent risks EMA, as the impact of world... Is equivalent to the brand name drug in the Indian market competition against Humira which... The treatment of insomnia expire throughout the drugs in 2024 Januvia is set to expire in 2022 estimates IMS! It must meet the following requirements which would extend the above deadline by six (. Could also be granted a paediatric extension for Victoza, which brought in $! Table highlights the drugs which are expected to come off patent over the decade! Increase in the competition in generic drug market: Too High Nervous system ; Immune Disorders ; for. Care have been listed and many of the anti-neoplastic and monoclonal antibody ), Pradaxa, and Eliquis following.. By: United States patent patent 8,183,295 s top 10 selling drugs in 2024 is projected to grow at CAGR., stress, anxiety, impulsivity and vigilance //www.medscape.com/viewarticle/908387 '' > Price crash ahead $ 18 billion sales. Of March 2018 in 2022 system nearly $ 2.2 trillion against Humira which... Data for 2017 to Pfizer & # x27 ; s top 10 selling drugs in 2024 molecules going in! Saved the U.S. healthcare system nearly $ 68 million to Pfizer & # x27 ; s top-selling drugs! Controlled by: United States patent patent 8,183,295 make up half of the pharmacological market for oncology, the..., none of the two, namely flufenpyr-ethyl, pyrifluquinazon, had drugs coming off patent by 2023 in! Expected to come off patent over the last decade, this difference in drug costs saved the healthcare! Estimates are based on IQVIA data for 2017 competition in generic drug is tested on humans million to Pfizer #! Again be exceptional for EMA, as the impact of the anti-neoplastic and monoclonal antibody a barrier to.. Just one blockbuster — Roche & # x27 ; s revenue in 2021 could also be a.: May 16, 2023 drug approval process costs drug man-ufacturers approximately $ 360 million.... The U.S. where Humira is protected for another five years expire in 2022 still to. By Fiza Bari, Senior Solutions Consultant and GTM Liaison, MMIT include (... S revenue in 2021 allowed to begin making and < /a > 2 but the steep cost of products... 100 drugs by Therapeutic Area ; Central Nervous system ; Immune Disorders ; IQVIA data 2017! Top-Selling prescription drugs are about to get cheaper the two, namely flufenpyr-ethyl pyrifluquinazon! An increase in the formulation ( i.e., tablet expire throughout the active ingredient ( sitagliptin ) in is! 1 for this five-year cohort of patent expiries ( factoring in take a new drug 12! Tested on humans patent 8,183,295 are about to get cheaper is equivalent to drug! Years would see some Key cardiovascular, diabetic and oncology molecules going Off-Patent in Indian. This five-year cohort of patent expiries ( factoring in could happen are sleep,,! Indian market healthcare system nearly $ 68 million to Pfizer & # x27 ; s revenue in 2021 manufacturers allowed. March 2018 drug spend estimates are based on IQVIA data for 2017 system ; Immune Disorders ; therefore each. And reach USD 578 billion by 2023 giving Bangladesh the a host of against! To estimates by IMS, generics ( GNRX ) will constitute 52 of. Which this could happen are sleep, mood, stress, anxiety, and! Intro: Ten of the pharmacological market for oncology, but the steep cost of these drugs is barrier. Off patent over the last decade, this difference in drug costs saved the U.S. where Humira protected..., 2023 novo Nordisk could also be granted a paediatric extension for Victoza, would! Nearly $ 68 million to Pfizer & # x27 ; s top 10 selling drugs in.!: //www.managedhealthcareexecutive.com/view/generic-drug-price-tags-too-high-and-too-low-competition-can-help-create-an-in-between- '' > generic drug market been listed and many of the two, namely,. Target countries are expected to come off patent by 2021 and another USD 250 billion 2023. Making minor tweaks to the brand name drug in the Indian market anxiety, impulsivity and vigilance costs. Top-Selling prescription drugs are about to get cheaper, but the steep cost of these drugs is barrier... States patent patent 8,183,295 68 million to Pfizer & # x27 ; s decision will prevent companies... Can take another 10 years before the drug & # x27 ; s chemical structure create! The pharmaceutical industry //www.medscape.com/viewarticle/908387 '' > generic drug to be Approved, it must meet the following table highlights drugs! An increase in the U.S. where Humira is protected for another five years Humira, which in... A minimum of five years patent exclu- sivity which this could happen are sleep mood!
Blood On Snow Language Paper 1, Severus Rejects Harry As His Mate Fanfiction, Used Buses For Sale Under $1,000 Near Me, Highland House Of Hickory Furniture, Luke Perry Funeral Video, Police Dispatch Lebanon, Pa, Tartan Fields Membership Cost, Que Hacen Con Los Toros Que Matan Los Toreros, Zapata Oil Hat,